Genfit S.A. (GNFT) Stock

About Genfit S.A.

Genfit S.A. operates as a biopharmaceutical company dedicated to discovering and advancing novel therapeutic candidates and diagnostic solutions for a range of metabolic and liver-related diseases. Its most advanced drug candidate, Elafibranor, is currently undergoing Phase 3 clinical evaluation for the treatment of primary biliary cholangitis (PBC). Beyond therapeutics, Genfit is also developing its NIS4 technology, designed to aid in the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company's pipeline further encompasses GNS561, which is in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation as a potential therapy for acute-on-chronic liver failure. Genfit has established strategic partnerships, including a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Additionally, it collaborates with Genoscience Pharma to jointly develop and market the investigational treatment GNS561 for CCA. Founded in 1999, Genfit S.A. is headquartered in Loos, France.

Genfit S.A. is headquartered in FR.

Genfit S.A. (GNFT) stock trades at $8.95 with a market capitalization of $445.68M. The stock is valued at a price-to-earnings (P/E) ratio of 261.07, price-to-book of 5.68, price-to-sales of 5.82. Over the past 52 weeks the stock has ranged between $2.55 and $10.00, and currently trades 10.5% below its 52-week high.

On profitability, Genfit S.A. generates a return on equity (ROE) of 2.20%, return on capital employed of 4.30%, an operating margin of 4.90%, a net profit margin of 2.25%.

Official website: www.genfit.com

Genfit S.A. by the numbers, 2015–2024

Between 2015 and 2024 Genfit S.A. reported revenue of $1.0M rising to $67.0M, a change of +6600.0% across 10 years. Compounded, revenue has grown 16.7% a year over five years, -5.7% over three, 131.0% over the last twelve months. Net profit rose to $2.0M.

Operating margin went from -3354.1% in 2015 to 4.9% in 2024, a gain of 3359.0 percentage points. The most recent net margin is 2.25%. On a trailing twelve-month basis to Jun '25, revenue is $117.0M and net profit $-17.0M.

Borrowings rose from $6.0M to $62.0M, cash on hand is $107.5M, cash from operations was $15.0M in the latest year, positive in 2 of the last 10.

Return on equity has averaged 124.5% over five years, and was 2.9% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Genfit S.A. (GNFT) — frequently asked questions